Soft Robotic Cardiac Sleeves: A New Frontier in Heart Failure Treatment
- Soft robotic cardiac sleeves are emerging as a non-blood-contact mechanical circulatory support device designed to augment myocardial function while avoiding direct interaction with circulating blood, according to a...
- Although contemporary pharmacological therapies have improved survival, heart failure remains associated with a five-year mortality rate exceeding 50 percent, underscoring its progressive and life-limiting nature, according to the...
- Unlike conventional ventricular assist devices that interact directly with blood flow, these systems augment cardiac function through synchronized external actuation of the myocardium.
Soft robotic cardiac sleeves are emerging as a non-blood-contact mechanical circulatory support device designed to augment myocardial function while avoiding direct interaction with circulating blood, according to a review published in Nature Communications by Javad Foroughi and colleagues. Heart failure remains a leading global cause of morbidity and mortality, affecting an estimated global prevalence exceeding 64 million individuals and placing a significant burden on healthcare systems through high rates of hospitalization and associated costs.
Global Burden of Heart Failure and Limitations of Current Therapies
Although contemporary pharmacological therapies have improved survival, heart failure remains associated with a five-year mortality rate exceeding 50 percent, underscoring its progressive and life-limiting nature, according to the review by Javad Foroughi and co-authors. A significant proportion of patients progress to end-stage disease characterized by irreversible myocardial damage and severely limited cardiac reserve. While heart transplantation remains the definitive treatment for end-stage heart failure, its application is fundamentally constrained by a severe shortage of donor organs. Savarese and colleagues in Cardiovascular Research. Contemporary mechanical circulatory support technologies are also associated with substantial complications, including thrombosis, infection, driveline failure, and the requirement for lifelong anticoagulation. Furthermore, most contemporary ventricular assist devices generate continuous, non-pulsatile blood flow that deviates from physiological hemodynamics, potentially contributing to additional clinical complications. These limitations have driven increasing interest in non-blood-contact approaches capable of augmenting cardiac function without direct interaction with circulating blood.
Design and Advantages of Soft Robotic Cardiac Sleeves
T. Roche and colleagues in Science Translational Medicine. Unlike conventional ventricular assist devices that interact directly with blood flow, these systems augment cardiac function through synchronized external actuation of the myocardium. By avoiding direct blood contact, soft robotic sleeves may reduce clinical complications, while their compliant, modular architectures enable adaptation to patient-specific anatomy, pathology, and disease severity. Soft robotic cardiac sleeves represent a technology-enabled evolution of historical cardiomyoplasty concepts, replacing autologous skeletal muscle with engineered, electrically or pneumatically actuated artificial muscles. These systems provide programmable, fatigue-resistant, and synchronized pulsatile epicardial assistance. Soft-robotic actuation strategies enable replication of the dynamic range, anisotropy, and spatiotemporal complexity of myocardial contraction, according to the engineering analysis by Javad Foroughi, Hojjatollah Nazari, Nigel Lovell, Christopher Hayward, Chun H. Wang, and Arjang Ruhparwar.
Engineering Challenges and Clinical Translation Roadmap
The successful clinical implementation of soft robotic cardiac sleeves requires overcoming key engineering and translational challenges, including long-term material durability, power transmission, and precise control algorithms for synchronization with native heartbeats. The review authors propose a translational framework to guide the future development of clinically viable soft robotic cardiac sleeves, addressing both physiological integration and device reliability. Alongside advanced strategies such as genetically modified cardiac xenotransplantation, stem-cell-based therapies, and tissue-engineering approaches, soft robotic sleeves offer a promising adjunctive therapy for managing advanced heart failure.
